

DRUG INTERACTIONS

Effects of other drugs on eletriptan

CYP3A4 inhibitors: *In vitro* studies have shown that eletriptan is metabolized by the CYP3A4 enzyme.

Ketoconazole: A clinical study demonstrated about a 3-fold increase in C_{max} and about a 6-fold increase in the AUC of eletriptan when co-administered with ketoconazole. The half-life of eletriptan increased from 5 h to 8 h and the T_{max} increased from 2.8 h to 5.4 h.

Erythromycin: A clinical study demonstrated about a 2-fold increase in eletriptan C_{max} and about a 4-fold increase in AUC when erythromycin was co-administered with eletriptan. This increased exposure was associated with an increase in eletriptan half-life from 4.6 h to 7.1 h.

Fluconazole: Co-administration of fluconazole and eletriptan yields about a 1.4-fold increase in C_{max} and about a 2-fold increase in AUC of eletriptan.

Verapamil: It has also been shown that co-administration of verapamil and eletriptan yields about a 2-fold increase in C_{max} and about a 3-fold increase in AUC of eletriptan.

Propranolol: The C_{max} and AUC of eletriptan were increased by 10% and 33%, respectively, following an 80 mg BID dose of propranolol administered for 7 days. No interactive increases in blood pressure were observed. No dose adjustment is necessary for patients also taking propranolol.

MAO inhibitors: Eletriptan is not a substrate for monoamine oxidase (MAO) enzymes. Therefore there is no expectation of an interaction between RELPAX and MAO inhibitors.

The effect of eletriptan on other drugs

The effect of eletriptan on enzymes other than cytochrome P450 has not been investigated. *In vitro* human liver microsome studies suggest that eletriptan has little potential to inhibit CYP1A2, 2C9, 2E1 and 3A4 at concentrations up to 100 μ M. While eletriptan has an effect on CYP2D6 at high concentration (IC_{50} of about 41 μ M), this effect should not interfere with metabolism of other drugs when eletriptan is used at recommended doses. There is no *in vitro* or *in vivo* evidence that clinical doses of eletriptan will induce drug metabolizing enzymes. Therefore, eletriptan is unlikely to cause clinically important drug interactions mediated by these enzymes.

Drug-herb interactions

Interactions with herbal products have not been established.

Drug-laboratory interactions

Interactions with laboratory tests have not been established.

SYMPTOMS AND TREATMENT OF OVERDOSE

Symptoms: No significant overdoses in clinical trials have been reported. Twenty-one (21) subjects have received single doses of 120 mg in Phase 1 trials and 427 in Phase 2/3 trials without significant adverse effects. Based on the pharmacology of 5-HT₁ agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.

Treatment: In case of overdose, standard supportive measures should be adopted. The elimination half-life of eletriptan is about 4 h, and therefore monitoring of patients after overdose with eletriptan should continue for at least 20 h, or longer should symptoms or signs persist. There is no specific antidote to eletriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentration of eletriptan.

For complete prescribing information, please refer to the Product Monograph. The full Product Monograph can be found at: www.pfizer.ca or by contacting the Pfizer Canada Inc. Medical Information Services at: 1-800-463-6001.



RELPA[®] Pfizer Products Inc., owner/Pfizer Canada Inc., Licensee
© 2010 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



See our AD on A-7



ADVERTISERS INDEX

Athena Diagnostics	OBC
CNSF Sponsors	A-6
Elekta	IFC
Interior Health	A-16
King Medical	A-15
Pfizer	
-Relpax	A-7, A-12 to A-15
Scotia Bank	IBC, A-8
Teva Canada Inovation	A-3
Vancouver Island Health Authority	A-15



KING MEDICAL THE CANADIAN ELECTRODE PLACE

- ALPINE BIOMED Mono/Conc. Needles
- AMBU Blue Sensor • Neuroline
- CHALGREN Needles • Bar/Ring/Clip
- KENDALL Adhesive • NuTab
- KING MEDICAL Cables & Adapters
- MAVIDON Lemon Skin Prep
- PARKER LAB. Electrode Paste
- RADIANT Infrared Skin Thermometer
- 3M CANADA Micropore • Transpore
- D.O. WEAVER Ten20 • NuPrep

Clavis™ • Chalgren • Inoject™
Large stock of Hypodermic Needles

Tel 905-833-3545 Fax 905-833-3543
E-mail: soren@kingmedical.com
Web Site: www.kingmedical.com

King Medical Ltd.
145 Kingsworth Road
King City • Ontario L7B 1K1

City life on Island time

Neurologist

Victoria, British Columbia

The Division of Neurology of the Vancouver Island Health Authority is recruiting a full-time Neurologist to practise in Victoria commencing December 2010.

In this position, you will work as an attending physician in the Multiple Sclerosis Clinic and direct this clinic. You will join the Division of Neurology and participate in paid on-call coverage with 9 other members. The Division provides services to a 350,000 direct referral population and a tertiary referral population of 750,000.

FRCPC Neurology certification, Fellowship training in Multiple Sclerosis and a minimum of one year post-Fellowship clinical experience are required.

Victoria is one of Canada's most livable cities—big city amenities with a small-town feel. Discover Victoria—with unlimited possibilities for your career, family and future!

Please forward your CV and the names of three references to:

Brenda Warren
Leader Physicians Recruitment
Email: physicians@viha.ca or
fax: 250.716.7747

VANCOUVER ISLAND
health
authority
viha.ca